199 related articles for article (PubMed ID: 36166639)
1. Novel Calcium-Binding Ablating Mutations Induce Constitutive RET Activity and Drive Tumorigenesis.
Tabata J; Nakaoku T; Araki M; Yoshino R; Kohsaka S; Otsuka A; Ikegami M; Ui A; Kanno SI; Miyoshi K; Matsumoto S; Sagae Y; Yasui A; Sekijima M; Mano H; Okuno Y; Okamoto A; Kohno T
Cancer Res; 2022 Oct; 82(20):3751-3762. PubMed ID: 36166639
[TBL] [Abstract][Full Text] [Related]
2. Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations.
Kjaer S; Kurokawa K; Perrinjaquet M; Abrescia C; Ibáñez CF
Oncogene; 2006 Nov; 25(53):7086-95. PubMed ID: 16732321
[TBL] [Abstract][Full Text] [Related]
3. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.
Chappuis-Flament S; Pasini A; De Vita G; Ségouffin-Cariou C; Fusco A; Attié T; Lenoir GM; Santoro M; Billaud M
Oncogene; 1998 Dec; 17(22):2851-61. PubMed ID: 9879991
[TBL] [Abstract][Full Text] [Related]
4. The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype.
Carlomagno F; Salvatore G; Cirafici AM; De Vita G; Melillo RM; de Franciscis V; Billaud M; Fusco A; Santoro M
Cancer Res; 1997 Feb; 57(3):391-5. PubMed ID: 9012462
[TBL] [Abstract][Full Text] [Related]
5. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
6. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.
Ito S; Iwashita T; Asai N; Murakami H; Iwata Y; Sobue G; Takahashi M
Cancer Res; 1997 Jul; 57(14):2870-2. PubMed ID: 9230192
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations.
Takahashi M; Asai N; Iwashita T; Murakami H; Ito S
Recent Results Cancer Res; 1998; 154():229-36. PubMed ID: 10027003
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations.
Asai N; Iwashita T; Matsuyama M; Takahashi M
Mol Cell Biol; 1995 Mar; 15(3):1613-9. PubMed ID: 7532281
[TBL] [Abstract][Full Text] [Related]
9. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
[TBL] [Abstract][Full Text] [Related]
10. Expression and purification of the extracellular domain of wild-type humanRET and the dimeric oncogenic mutant C634R.
Liu Y; Ribeiro OC; Robinson J; Goldman A
Int J Biol Macromol; 2020 Dec; 164():1621-1630. PubMed ID: 32777409
[TBL] [Abstract][Full Text] [Related]
11. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.
Iwashita T; Asai N; Murakami H; Matsuyama M; Takahashi M
Oncogene; 1996 Feb; 12(3):481-7. PubMed ID: 8637703
[TBL] [Abstract][Full Text] [Related]
12. A novel type of mutation in the cysteine rich domain of the RET receptor causes ligand independent activation.
Arlt DH; Baur B; Wagner B; Höppner W
Oncogene; 2000 Jul; 19(30):3445-8. PubMed ID: 10918602
[TBL] [Abstract][Full Text] [Related]
13. Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells.
Hennige AM; Lammers R; Arlt D; Höppner W; Strack V; Niederfellner G; Seif FJ; Häring HU; Kellerer M
Mol Cell Endocrinol; 2000 Sep; 167(1-2):69-76. PubMed ID: 11000521
[TBL] [Abstract][Full Text] [Related]
14. Unexpected structures formed by the kinase RET C634R mutant extracellular domain suggest potential oncogenic mechanisms in MEN2A.
Liu Y; De Castro Ribeiro O; Haapanen O; Craven GB; Sharma V; Muench SP; Goldman A
J Biol Chem; 2022 Oct; 298(10):102380. PubMed ID: 35985422
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic activation of the ret protooncogene in thyroid cancer.
Takahashi M
Crit Rev Oncog; 1995; 6(1):35-46. PubMed ID: 8573606
[TBL] [Abstract][Full Text] [Related]
16. Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2.
Gujral TS; Mulligan LM
Ann N Y Acad Sci; 2006 Aug; 1073():234-40. PubMed ID: 17102091
[TBL] [Abstract][Full Text] [Related]
17. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A.
Landsvater RM; Jansen RP; Hofstra RM; Buys CH; Lips CJ; Ploos van Amstel HK
Hum Genet; 1996 Jan; 97(1):11-4. PubMed ID: 8557249
[TBL] [Abstract][Full Text] [Related]
18. Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation.
Bongarzone I; Vigano E; Alberti L; Borrello MG; Pasini B; Greco A; Mondellini P; Smith DP; Ponder BA; Romeo G; Pierotti MA
Oncogene; 1998 May; 16(18):2295-301. PubMed ID: 9620546
[TBL] [Abstract][Full Text] [Related]
19. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
Plaza Menacho I; Koster R; van der Sloot AM; Quax WJ; Osinga J; van der Sluis T; Hollema H; Burzynski GM; Gimm O; Buys CH; Eggen BJ; Hofstra RM
Cancer Res; 2005 Mar; 65(5):1729-37. PubMed ID: 15753368
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations.
Takahashi M; Asai N; Iwashita T; Murakami H; Ito S
J Intern Med; 1998 Jun; 243(6):509-13. PubMed ID: 9681851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
